Title:
METHOD OF TREATMENT USING LIGAND-IMMUNOGEN CONJUGATES
Document Type and Number:
WIPO Patent Application WO2001074382
Kind Code:
A9
Abstract:
A method and pharmaceutical composition is provided for enhancing the endogenous immune response-mediated elimination of a population of pathogenic cells in a host animal wherein the pathogenic cells preferentially express, uniquely express, or overexpress a binding site for a particular ligand. The invention comprises administering the ligand conjugated to an immunogen to a host animal harboring the population of pathogenic cells. Antibodies, preexisting or administered to the host animal to establish a passive immunity, directed against the immunogen bind to the ligand-immunogen conjugate resulting in elimination of the pathogenic cell by the host's immune response. At least one additional therapeutic factor is administered selected from the group consisting of a cell killing agent, a tumor penetration enhancer, a chemotherapeutic agent, antimicrobial agent, a cytotoxic immune cells, and a compound capable of stimulating an endogenous immune response wherein the compound does not bind to the ligand-immunogen conjugate.
Inventors:
LOW PHILIP STEWART
LU YINGJUAN
LU YINGJUAN
Application Number:
PCT/US2001/010254
Publication Date:
October 10, 2002
Filing Date:
March 30, 2001
Export Citation:
Assignee:
PURDUE RESEARCH FOUNDATION (US)
International Classes:
A61K35/14; A61K38/00; A61K39/00; A61K39/02; A61K39/12; A61K39/385; A61K39/39; A61K47/48; A61K39/395; A61K45/00; A61P31/00; A61P31/04; A61P31/10; A61P31/12; A61P33/00; A61P35/00; A61P35/02; A61P37/04; A61P43/00; (IPC1-7): A61K39/00; A61K39/395; A61K38/00; A61K31/63; A61K31/655; A61K31/04; A61K31/02
Download PDF: